Clinical Trial Update: Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of AVE2268 in patients with Type 2 Diabetes Mellitus not adequately controlled by metformin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AVE2268

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED